newest glp 1 medication New GLP-1 Pill Foundayo (Orforglipron) Gets FDA Approval for Obesity New research is taking a

June 25, 2025

[97] observed a potential association between semaglutide and NAION, with incidence rates of 4.28 and 7.64 per 1,000 person-years in patients with T2DM and those who were overweight or obese, respectively, over 36 months

One must have a BMI of 30 or above, or a BMI of at least 27 or above with a weight-related health condition like high blood pressure, diabetes, or high cholesterol

Keep shopping Post Wanted

Weight Loss Results for GLP-1 Shots vs

Many posts described using smaller doses, including semaglutide microdosing, as a way to manage side effects, extend medication supply, or navigate access barriers